AbCellera Biologics (ABCL) Equity Average: 2021-2025
Historic Equity Average for AbCellera Biologics (ABCL) over the last 5 years, with Sep 2025 value amounting to $985.6 million.
- AbCellera Biologics' Equity Average fell 9.96% to $985.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $985.6 million, marking a year-over-year decrease of 9.96%. This contributed to the annual value of $1.1 billion for FY2024, which is 7.43% down from last year.
- As of Q3 2025, AbCellera Biologics' Equity Average stood at $985.6 million, which was down 2.90% from $1.0 billion recorded in Q2 2025.
- AbCellera Biologics' 5-year Equity Average high stood at $1.2 billion for Q4 2022, and its period low was $893.8 million during Q1 2021.
- Moreover, its 3-year median value for Equity Average was $1.1 billion (2024), whereas its average is $1.1 billion.
- Its Equity Average has fluctuated over the past 5 years, first rose by 28.21% in 2022, then dropped by 9.96% in 2025.
- AbCellera Biologics' Equity Average (Quarterly) stood at $989.6 million in 2021, then rose by 25.48% to $1.2 billion in 2022, then fell by 5.97% to $1.2 billion in 2023, then fell by 8.60% to $1.1 billion in 2024, then decreased by 9.96% to $985.6 million in 2025.
- Its last three reported values are $985.6 million in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.